Last reviewed · How we verify
Shenzhen Kexing Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
1 Phase 2
1 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| SHEN26 capsule | SHEN26 capsule | phase 3 | vaccine | SARS-CoV-2 spike protein | Infectious Disease |
Therapeutic area mix
- Infectious Disease · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Aduro Biotech, Inc. · 1 shared drug class
- Aeras · 1 shared drug class
- Aga Khan University · 1 shared drug class
- Aimei Vacin BioPharm (Zhejiang) Co., Ltd. · 1 shared drug class
- Alba Maria Ropero · 1 shared drug class
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · 1 shared drug class
- Asoc. Prof. Erdoğan Selçuk Şeber · 1 shared drug class
- ANRS, Emerging Infectious Diseases · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Shenzhen Kexing Pharmaceutical Co., Ltd.:
- Shenzhen Kexing Pharmaceutical Co., Ltd. pipeline updates — RSS
- Shenzhen Kexing Pharmaceutical Co., Ltd. pipeline updates — Atom
- Shenzhen Kexing Pharmaceutical Co., Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Shenzhen Kexing Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shenzhen-kexing-pharmaceutical-co-ltd. Accessed 2026-05-17.